Skip to main content
Premium Trial:

Request an Annual Quote

ActivX Biosciences, Kyorin Pharmaceutical To Develop Diabetes Drugs

NEW YORK, June 4-ActivX Biosciences has inked a deal with Tokyo's Kyorin Pharmaceutical company to identify and optimize new drugs for type II diabetes, the company said today.


ActivX, which studies protein activity in disease, will develop assays, screen and profile hit and lead compounds. Kyorin will provide the company with research support, milestone payments, and royalties on any commercialized products. ActivX also retains rights for some compounds that may be active in other diseases.


Kyorin will conduct medicinal chemistry, animal pharmacology and clinical development on lead compounds. The company has worldwide manufacturing and marketing rights to any drugs developed in the collaboration.


ActivX is the Japanese pharmaceutical company's first U.S. biotechnology partner.


Based in La Jolla, ActivX studies disease mechanisms by analyzing protein activity.


For further details, read the press release.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.